Bio-Connect

Anti-CCR2 [MLN1202 (Plozalizumab, hu1D9)]

AB04182-3.0-BT
Absolute Antibody
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman
TargetCCR2
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-CCR2 [MLN1202 (Plozalizumab, hu1D9)]
  • Delivery Days Customer
    9
  • Antibody Specificity
    This antibody binds and epitope between amino acids 1-30 in the amino terminal region of human CC-chemokine receptor 2. CCR2 receptor is a key functional receptor for CCL2, a chemokine which specifically mediates monocyte chemotaxis. CCL2 is involved in m
  • Application Supplier Note
    The binding characterization of the original mouse parental antibody 1D9 for human CCR2 was done using flow cytometry. This humanized antibody was capable of inhibit the binding of [125I]-MCP-1 to whole THP-1 cells (US6696550). In a clinical trial study, in patients with active rheumatoid arthritis (RA), it was reported that treatment with anti-CCR2 blocking antibody did not result in amelioration of synovial inflammation in active RA (PMID: 18576354). In a study in patients with risk factors for atherosclerotic cardiovascular disease (ASCVD), it was reported that that blockade of CCR2 with MLN1202 reduces C-reactive protein, a biomarker related to inflammation in patients at risk for ASCVD (Davidson et. al., 2007). In another study, patients with ASCVD, who received MLN1202 exhibited significant decreases in high-sensitivity C-reactive protein levels, beginning at 4 weeks and continuing through 12 weeks after dosing (PMID: 21247529). A phase II clinical trial (NCT01015560) in patients with bone metastases resulting from unspecified solid tumors, reported that administration of MLN1202 was well tolerated in patients with < 8% reporting serious adverse events although only 14 patients (~32%) had a considerable reduction in urinary N-telopeptide values after 43 days of treatment (PMID: 26885690).
  • Applications
    Flow Cytometry, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    MLN1202 (Plozalizumab, hu1D9)
  • Gene ID729230
  • Target name
    CCR2
  • Target description
    C-C motif chemokine receptor 2
  • Target synonyms
    C-C chemokine receptor type 2; CC-CKR-2; CCR-2; CCR2A; CCR2B; CD192; chemokine (C-C motif) receptor 2; CKR2; CKR2A; CKR2B; CMKBR2; MCP-1 receptor; MCP-1-R; monocyte chemoattractant protein 1 receptor; monocyte chemotactic protein 1 receptor
  • Host
    Mouse
  • Isotype
    IgG2b
  • Protein IDP41597
  • Protein Name
    C-C chemokine receptor type 2
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203